SCHEDULE 13G/A: Prelude Therapeutics Insider Krishna Vaddi Discloses 13.8% Beneficial Ownership Stake

Krishna Vaddi, a key individual associated with Prelude Therapeutics Inc., has filed an amended Schedule 13G, disclosing a beneficial ownership of 13.8% of the company's common stock as of March 31, 2025.

Summary

• Krishna Vaddi, the Reporting Person, beneficially owns an aggregate of 6,397,839 shares of Prelude Therapeutics Inc. common stock.
• This ownership represents 13.8% of the company's outstanding common stock as of March 31, 2025.
• The beneficial ownership includes 4,728,081 shares directly owned by Mr. Vaddi (1,999,296 voting common stock and 2,728,785 shares underlying stock options exercisable within 60 days of March 31, 2025).
• Additionally, Mr. Vaddi is deemed to have beneficial ownership over shares held by Sidus Ventures, LLC (142,553 shares), Dolphin City Trust (423,655 shares), Blue Sky Trust (551,776 shares), and Brocade Trust (551,774 shares) due to his roles as manager, beneficiary, or investment advisor.
• The percentage ownership is calculated based on 43,604,202 shares of voting common stock outstanding as of March 31, 2025, as reported by the Issuer, plus the exercisable options held by Mr. Vaddi.
• This filing is Amendment No. 5 to the Schedule 13G, indicating an update to previously reported beneficial ownership.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future operations or financial performance.

Industry Context

This filing is a standard disclosure of significant beneficial ownership by an individual associated with a publicly traded company. It provides transparency regarding the ownership structure of Prelude Therapeutics Inc., which is common practice in the biotechnology or pharmaceutical industry where insider stakes can be significant.

Related Party Transactions

• Krishna Vaddi's beneficial ownership includes shares held by Sidus Ventures, LLC (where he is manager), Dolphin City Trust (where he is beneficiary), and Blue Sky Trust and Brocade Trust (where he is investment advisor). These entities are considered related parties for the purpose of beneficial ownership disclosure.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant insider ownership stake, which can influence investor perception of management alignment and confidence.
• Regulatory Authorities: Fulfills SEC disclosure requirements for significant beneficial ownership, ensuring market transparency.

Key Dates

Keywords

Prelude Therapeutics Inc., Krishna Vaddi, Beneficial Ownership, Schedule 13G, Common Stock, Insider Ownership, SEC Filing, PRLD